PER-037-04已完成未知
A 12-MONTH, RANDOMIZED, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM SAFETY OF ALISKIREN 150 MG ONLY AND 300 MG ONLY, OR WITH THE ADDITIONAL ADDED HYDROCHLOROTHIAZIDE (12.5 MG OR 25 MG) IN PATIENTS WITH ESSENTIAL HYPERTENSIO
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2004年7月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •their successful completion of the CSPP100A2302 core study with at least eight months combination treatment of aliskiren 300 mg and HCTZ 25 mg, i.e., patients who received aliskiren 300 mg and HCTZ 25 mg at Month 4 of the core study and complete the core study.
- •absence of ongoing severe adverse events at Visit 10.
排除标准
- •healthy people
- •pregnant women
研究者
相似试验
进行中（未招募）
4 期
To evaluate the effect & safety of two immunosuppresant drugs (Tacrolimus with Enteric coated Mycophenolate Sodium or Mycophenolate Mofetil) in new renal transplant recipients.CTRI/2012/02/002441ovartis Healthcare Pvt Ltd200
已完成
3 期
A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of Certican-based regimen versus calcineurin inhibitor-based regimen in de novo liver transplant recipientTherapy after Liver transplant10019654NL-OMON30363ovartis40
已完成
不适用
A MULTI-CENTER STUDY OF 52 WEEKS, RANDOMIZED, DOUBLE-BLIND, DOUBLED MASKED, CONTROLLED WITH PLACEBO AND PARALLEL GROUPS, TO COMPARE THE EFFECTIVENESS AND TOLERABILITY OF THE COMBINATION WITH SALMETEROL / PROPIONATO DE FLUTICASONA (SERETIDE / VIANI / ADV)-J45J45PER-026-02GLAXOSMITHKLINE PERU S.A.,
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyAlzheimer's diseaseEUCTR2004-004918-17-CZPfizer Inc100
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyMedDRA version: 7Level: VTcClassification code 10012271Alzheimer's diseaseEUCTR2004-004918-17-DEPfizer Limited100